2-[(2-t-butyl)-2H-tetrazol-5-yl]phenylboronic acid | 145733-49-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-[(2-t-butyl)-2H-tetrazol-5-yl]phenylboronic acid
• 英文别名: 2-[(1-tert-butyl)-1H-tetrazol-5-yl]phenylboronic acid；[2-(1-tert-butyltetrazol-5-yl)phenyl]boronic acid
• CAS: 145733-49-9
• 化学式: C₁₁H₁₅BN₄O₂
• 分子量: 246.077
• InChiKey: CYPDJVJMGNAVIQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.23
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  84.1
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  8-[(4-溴苯基)甲基]-5,8-二氢-2,4-二甲基吡啶并[2,3-D]嘧啶-7(6H)-酮 、 2-[(2-t-butyl)-2H-tetrazol-5-yl]phenylboronic acid 在 四(三苯基膦)钯 三乙胺 作用下， 以 氯仿 、 N,N-二甲基甲酰胺 为溶剂， 以1.05 g (66%)的产率得到2,4-dimethyl-5,6,8-trihydro-8-[[2'-(1-tert-butyl-1H-tetrazol-5-yl)[1,1-biphenyl]-4-yl]methyl]-7H-pyrido[2,3-d]pyrimidin-7-one
  参考文献：
  名称：

  Substituted pyridopyrimidines useful as antgiotensin II antagonists

  摘要：

  本发明涉及一般式I的吡咯基、吡啶基、氮杂七元环和氮杂环丙嘧啶类化合物，对治疗高血压和充血性心力衰竭有用，还涉及制药组合物及其生产方法。

  公开号：

  US05149699A1
• 作为产物：
  描述：

  5-(2-bromophenyl)-1-tert-butyl-1H-tetrazole 、 硼酸三异丙酯 、 1,2-二溴乙烷 在 盐酸 作用下， 以 四氢呋喃 为溶剂， 以306 mg (48%)的产率得到2-[(2-t-butyl)-2H-tetrazol-5-yl]phenylboronic acid
  参考文献：
  名称：

  Substituted pyridopyrimidines useful as antgiotensin II antagonists

  摘要：

  本发明涉及一般式I的吡咯基、吡啶基、氮杂七元环和氮杂环丙嘧啶类化合物，对治疗高血压和充血性心力衰竭有用，还涉及制药组合物及其生产方法。

  公开号：

  US05149699A1

文献信息

• Substituted pyridopyrimidines useful as antgiotensin II antagonists
  申请人：American Home Products Corporation

  公开号：US05149699A1

  公开（公告）日：1992-09-22

  This invention relates to pyrrolo-, pyrido-, azepino-, and azocinopyrimidines of the general formula I ##STR1## useful for treating hypertension and congestive heart failure, to pharmaceutical compositions, and to methods for production thereof.

  本发明涉及一般式I的吡咯基、吡啶基、氮杂七元环和氮杂环丙嘧啶类化合物，对治疗高血压和充血性心力衰竭有用，还涉及制药组合物及其生产方法。
• Substituted pyridopyrimidines and antihypertensives
  申请人：American Home Products Corporation

  公开号：US05466692A1

  公开（公告）日：1995-11-14

  This invention relates to substituted pyridopyrimidinones of general formula (I): ##STR1## wherein R.sup.1 and R.sup.2 are independently H, lower alkyl containing 1 to 6 carbon atoms, hydroxyalkyl containing 1 to 6 carbon atoms, formyl, carbonylalkyl containing 1 to 6 carbon atoms, carboxy, or carboxyalkyl containing 1 to 6 carbon atoms; R.sup.3 and R.sup.4 are independently H, lower alkyl containing 1 to 6 carbon atoms, hydroxy; R.sup.3a and R.sup.4a are H, and when taken together with R.sup.3 and R.sup.4 respectively comprise a carbonyl; with the proviso that at least one of the groups R1 and R.sup.2 must be hydroxyalkyl, formyl, carbonylalkyl containing 1 to 6 carbon atoms, carboxy, or carboxyalkyl containing 1 to 6 carbon atoms; or R.sup.3 and R.sup.4 must be hydroxy or taken together with R.sup.3a and R.sup.4a respectively must comprise a carbonyl; n is 0 to 3; Ar.sup.1 is ##STR2## wherein W is H, lower alkyl containing 1 to 6 carbon atoms, halogen, hydroxy, or lower alkoxy containing 1 to 6 carbon atoms; Ar.sup.2 is ##STR3## wherein X is CO.sub.2 H, CN, or ##STR4## wherein R.sup.5 is H, CH.sub.3, tert-butyl, tri-n-butylstannyl, or triphenylmethyl; and the pharmaceutically acceptable salts thereofuseful for treating hypertension and congestive heart failure, to pharmaceutical compositions, and to methods for production thereof.

  这项发明涉及通式（I）的取代吡啶吡嘧啶酮：其中R.sup.1和R.sup.2分别是H、含有1至6个碳原子的较低烷基、含有1至6个碳原子的羟基烷基、甲酰基、含有1至6个碳原子的羰基烷基、羧基或含有1至6个碳原子的羧基烷基；R.sup.3和R.sup.4分别是H、含有1至6个碳原子的较低烷基、羟基；R.sup.3a和R.sup.4a是H，且与R.sup.3和R.sup.4分别结合时包括一个羰基；但必须至少有R1和R.sup.2中的一个是羟基烷基、甲酰基、含有1至6个碳原子的羰基烷基、羧基或含有1至6个碳原子的羧基烷基；或R.sup.3和R.sup.4必须是羟基，或者与R.sup.3a和R.sup.4a分别结合时必须包括一个羰基；n为0至3；Ar.sup.1为其中W为H、含有1至6个碳原子的较低烷基、卤素、羟基或含有1至6个碳原子的较低烷氧基；Ar.sup.2为其中X为CO.sub.2 H、CN或其中R.sup.5为H、CH.sub.3、叔丁基、三正丁基锡基或三苯基甲基；及其药用盐，用于治疗高血压和充血性心力衰竭，制药组合物以及其生产方法。
• Substituted pyrrolopyrimidines and pyridopyrimidines useful as
  申请人：American Home Products Corporation

  公开号：US05498776A1

  公开（公告）日：1996-03-12

  This invention relates to pyrrolo-, pyrido-, azepino-, and azocinopyrimidines of the general formula I ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are independently H, lower alkyl containing 1 to 6 carbon atoms, or perfluoroalkyl containing 1 to 6 carbon atoms; R.sup.5 is H or, when n is 1, R.sup.5 taken together with R.sup.3 comprises a double bond, n is 0 or 1, p is 0 to 2, m is 0 to 3; Ar.sup.1 is ##STR2## wherein W is H, lower alkyl containing 1 to 6 carbon atoms, halogen, hydroxy, or lower alkoxy containing 1 to 6 carbon atoms; and Ar.sup.2 is ##STR3## wherein X is ##STR4## wherein R.sup.6 is H, tert-butyl, tri-n-butylstannyl, or triphenylmethyl; and the pharmaceutically acceptable salts thereof, which compounds are useful in the treatment of hypertension and congestive heart failure.

  本发明涉及一般式I的吡咯烷、吡啶烷、氮杂环庚烷和氮杂环壬烷基嘧啶类化合物，其中R1、R2、R3和R4分别独立地为H、含有1至6个碳原子的低碳烷基或含有1至6个碳原子的全氟烷基；R5为H或当n为1时，R5与R3结合成双键；n为0或1；p为0至2；m为0至3；Ar1为##STR2##其中W为H、含有1至6个碳原子的低碳烷基、卤素、羟基或含有1至6个碳原子的低碳基氧基；Ar2为##STR3##其中X为##STR4##其中R6为H、叔丁基、三正丁基锡基或三苯基甲基；以及其药学上可接受的盐，这些化合物在治疗高血压和充血性心力衰竭方面有用。
• Novel human metabolites of the angiotensin-II antagonist tasosartan and their pharmacological effects
  作者：Hassan M Elokdah、Gregory S Friedrichs、Sie-Yearl Chai、Boyd L Harrison、John Primeau、Michael Chlenov、David L Crandall

  DOI：10.1016/s0960-894x(02)00303-7

  日期：2002.8

  Three novel metabolites of the angiotensin-II (A-II) receptor antagonist tasosartan have been identified in humans, and the syntheses and pharmacologic profiling of these metabolites are reported. Each metabolite bound the human A-II receptor with IC(50)s between 20 and 45 nM. The in vivo effects of these compounds in attenuating the pressor response to angiotensin-II challenge in anesthetized rats were also investigated. An unsaturated diol metabolite exhibited in vivo efficacy at intravenous doses of 1 and 3 mg/kg, while the other metabolites, both carboxylic acids, had no significant effect at the same doses. (C) 2002 Elsevier Science Ltd. All rights reserved.
• Substituted pyrrolopyrimidines, azepinopyrimidines and pyridopyrimidines
  申请人：American Home Products Corporation

  公开号：US05256654A1

  公开（公告）日：1993-10-26

  This invention relates to pyrrolo-, pyrido-, azepino-, and azocinopyrimidines of the general formula I ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are independently H, lower alkyl containing 1 to 6 carbon atoms, or perfluoroalkyl containing 1 to 6 carbon atoms; R.sup.5 is H or when n is 1 R.sup.5 taken together with R.sup.3 comprises a double bond; n is 0 to 1; p is 0 to 2; m is 0 to 3; Ar.sup.1 is ##STR2## wherein W is H, lower alkyl containing 1 to 6 carbon atoms, halogen, hydroxy, or lower alkoxy containing 1 to 6 carbon atoms; Ar.sup.2 is ##STR3## wherein X is ##STR4## wherein R.sup.6 is H, tert-butyl, tri-n-butylstannyl, or triphenylmethyl; and the pharmaceutically acceptable salts thereof which by virtue of their ability to antagonize angiotensin II are useful for the treatment of hypertension, congestive heart failure, and restenosis. The compounds are also useful for reducing lipid levels in the blood plasma and are thus useful for treating hyperlipidemia and hypercholesterolemia. Also disclosed are processes for the production of said compounds and pharmaceutical compositions containing said compounds.

  这项发明涉及一般式I的吡咯烯、吡啶烯、氮杂七元环和氮杂七元杂环嘧啶类化合物，其中R.sup.1、R.sup.2、R.sup.3和R.sup.4分别独立地为H、含有1至6个碳原子的较低烷基，或含有1至6个碳原子的全氟烷基；R.sup.5为H，当n为1时，R.sup.5与R.sup.3一起构成双键；n为0至1；p为0至2；m为0至3；Ar.sup.1为##STR2##其中W为H、含有1至6个碳原子的较低烷基、卤素、羟基或含有1至6个碳原子的较低烷氧基；Ar.sup.2为##STR3##其中X为##STR4##其中R.sup.6为H、叔丁基、三正丁基锡基或三苯甲基；以及它们的药用可接受盐，由于它们具有拮抗血管紧张素II的能力，因此可用于治疗高血压、充血性心力衰竭和再狭窄。这些化合物还可用于降低血浆中的脂质水平，因此可用于治疗高脂血症和高胆固醇血症。还公开了生产这些化合物的方法和含有这些化合物的药物组合物。